1. Home
  2. GSIT vs CRDF Comparison

GSIT vs CRDF Comparison

Compare GSIT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GSI Technology

GSIT

GSI Technology

HOLD

Current Price

$7.32

Market Cap

213.6M

Sector

Technology

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.62

Market Cap

187.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIT
CRDF
Founded
1995
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.6M
187.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GSIT
CRDF
Price
$7.32
$1.62
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.83
AVG Volume (30 Days)
1.8M
1.6M
Earning Date
01-29-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,024,000.00
$501,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.00
N/A
52 Week Low
$1.62
$1.62
52 Week High
$18.15
$4.99

Technical Indicators

Market Signals
Indicator
GSIT
CRDF
Relative Strength Index (RSI) 48.83 25.61
Support Level $7.10 $2.72
Resistance Level $8.05 $3.05
Average True Range (ATR) 0.91 0.19
MACD -0.07 -0.17
Stochastic Oscillator 18.26 0.30

Price Performance

Historical Comparison
GSIT
CRDF

About GSIT GSI Technology

GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: